{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:25:18Z","timestamp":1774347918495,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipid-lowering medication reduces the risk of future cardiovascular events and mortality, yet adherence is often disappointing. This study evaluates adherence rates of lipid-lowering medication and its subtypes during the first year following acute and elective percutaneous coronary intervention (PCI) in the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study utilized data from a\u00a0nationwide all-payer claims database managed by Vektis, containing all medical care claims reimbursed by Dutch national insurance companies. We included 97,176 patients who underwent PCI in 2018\u20132020. Adherence was defined as a\u00a0medication possession rate \u2265\u202f80%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adherence rates 0\u20133\u00a0months post-elective PCI ranged from 71\u201373% among the years and remained stable over the year following PCI. For acute PCI, adherence rates 0\u20133\u00a0months post-acute PCI were initially higher (79\u201381%) but declined to 74\u201376% during the year following PCI.<\/jats:p>\n                    <jats:p>During the year following PCI, adherence rates for ezetimibe and proprotein convertase subtilisin\/kexin type\u00a09 (PCSK9) inhibitors increased slightly to about 13%, respectively 2%, while statin adherence decreased. For statin subtypes, adherence rates for rosuvastatin increased at the expense of simvastatin, with adherence for atorvastatin and other statins remaining relatively stable. Lower adherence rates were observed among females and patients \u2265\u202f80\u00a0years compared to males and younger patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study found lipid-lowering medication adherence 1\u00a0year post-elective PCI ranged from 71\u201373% and post-acute PCI from 74\u201376%. Lower adherence rates were observed in women and elderly patients. Adherence rates of ezetimibe and PCSK9 inhibitors increased throughout the year following PCI, while statin use decreased.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12471-026-02028-8","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:11:09Z","timestamp":1772453469000},"page":"143-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medication adherence to lipid-lowering agents after percutaneous coronary intervention: nationwide real-world data in the Netherlands"],"prefix":"10.1007","volume":"34","author":[{"given":"Marijke J. C.","family":"Timmermans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Patrick","family":"Witvliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"van Erkelens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Reitsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter W.","family":"Kamphuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Camaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Danse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Karin","family":"Arkenbout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"PCI Registration Committee of the Netherlands Heart Registration","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"2","key":"2028_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/hrt.2007.140905","volume":"95","author":"AJ Kerr","year":"2009","unstructured":"Kerr\u00a0AJ, Broad\u00a0J, Wells\u00a0S, Riddell\u00a0T, Jackson\u00a0R. Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart. 2009;95(2):125.","journal-title":"Heart"},{"issue":"34","key":"2028_CR2","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM, et\u00a0al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Euro Heart J. 2021;42(34):3227\u201337.","journal-title":"Euro Heart J"},{"issue":"9841","key":"2028_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"Cholesterol Treatment Trialists Collaborators","year":"2012","unstructured":"Cholesterol Treatment Trialists Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet. 2012;380(9841):581\u201390.","journal-title":"The Lancet"},{"issue":"9753","key":"2028_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration, Baigent\u00a0C, Blackwell\u00a0L, et\u00a0al. Efficacy and safety of more intensive lowering of LDL cholesterol: a\u00a0meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"32","key":"2028_CR5","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference\u00a0BA, et\u00a0al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"10263","key":"2028_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","volume":"396","author":"B Gencer","year":"2020","unstructured":"Gencer\u00a0B, Marston\u00a0NA, Im\u00a0K, et\u00a0al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637\u201343.","journal-title":"Lancet"},{"key":"2028_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0283-6","volume":"16","author":"S Halvorsen","year":"2016","unstructured":"Halvorsen\u00a0S, et al. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. BMC Cardiovasc Disord. 2016;16:115.","journal-title":"BMC Cardiovasc Disord"},{"issue":"19","key":"2028_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","volume":"36","author":"T Jernberg","year":"2015","unstructured":"Jernberg\u00a0T, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a\u00a0long-term perspective. Eurn Heart Journal. 2015;36(19):1163\u201370.","journal-title":"Eurn Heart Journal"},{"issue":"9","key":"2028_CR9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","volume":"125","author":"SH Naderi","year":"2012","unstructured":"Naderi\u00a0SH, Bestwick\u00a0JP, Wald\u00a0DS. Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients. Am J of Med. 2012;125(9):882\u2013887.e1.","journal-title":"Am J of Med"},{"issue":"2","key":"2028_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/2047487317744363","volume":"25","author":"DC Eindhoven","year":"2020","unstructured":"Eindhoven\u00a0DC, et al. Age and gender differences in medical adherence after myocardial infarction: Women do not receive optimal treatment \u2013 The Netherlands claims database. Eur J Prev Cardiol. 2020;25(2):181\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2028_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12471-017-1055-3","volume":"26","author":"DC Eindhoven","year":"2018","unstructured":"Eindhoven\u00a0DC, van Staveren\u00a0LN, van Erkelens\u00a0JA, et\u00a0al. Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands. Neth Heart J. 2018;26(1):13\u201320.","journal-title":"Neth Heart J"},{"issue":"15","key":"2028_CR12","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","volume":"31","author":"KK Ray","year":"2024","unstructured":"Ray\u00a0KK, Aguiar\u00a0C, Arca\u00a0M, et\u00a0al. Use of combination therapy is associated with improved LDL cholesterol management: 1\u2011year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024;31(15):1792\u2013803.","journal-title":"Eur J Prev Cardiol"},{"key":"2028_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray\u00a0KK, Haq\u00a0I, Bilitou\u00a0A, et\u00a0al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"2028_CR14","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray\u00a0KK, Molemans\u00a0B, Schoonen\u00a0WM, et\u00a0al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"2028_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12471-022-01672-0","volume":"30","author":"MJC Timmermans","year":"2022","unstructured":"Timmermans\u00a0MJC, Houterman\u00a0S, Daeter\u00a0ED, et\u00a0al. Using real-world data to monitor and improve quality of care in coronary artery disease: results from the Netherlands Heart Registration. Neth Heart J. 2022;30(12):546\u201356.","journal-title":"Neth Heart J"},{"key":"2028_CR16","unstructured":"De Staat van Volksgezondheid en Zorg. Number of people without health insurance - trends throughout the years [Available from: https:\/\/www.staatvenz.nl\/kerncijfers\/onverzekerden-zorgverzekering]."},{"issue":"2","key":"2028_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.15386\/mpr-1201","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel\u00a0LA, Farcas\u00a0AM, Oprean\u00a0RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117\u201322.","journal-title":"Med Pharm Rep"},{"key":"2028_CR18","unstructured":"Ministry of Health, Welfare and Sport. Socio-economic status per region [Available from: https:\/\/www.vzinfo.nl\/sociaaleconomische-status\/regionaal\/algemeen]."},{"issue":"6","key":"2028_CR19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3949\/ccjm.70.6.502","volume":"70","author":"GC Fonarow","year":"2003","unstructured":"Fonarow\u00a0GC. In-hospital initiation of statins: taking advantage of the \u2019teachable moment\u2019. Cleve Clin J Med. 2003;70(6):502\u20136.","journal-title":"Cleve Clin J Med"},{"issue":"10","key":"2028_CR20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","volume":"27","author":"GH Gislason","year":"2006","unstructured":"Gislason\u00a0GH, Rasmussen\u00a0JN, Abildstr\u00f8m\u00a0SZ, et\u00a0al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153\u20138.","journal-title":"Eur Heart J"},{"issue":"17","key":"2028_CR21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes\u00a0ES, Thompson\u00a0PD, Corsini\u00a0A, et\u00a0al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"key":"2028_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/PPA.S245365","volume":"14","author":"MV Ingersgaard","year":"2020","unstructured":"Ingersgaard\u00a0MV, et al. Reasons for Nonadherence to Statins - A Systematic Review of Reviews. Patient Prefer Adherence. 2020;14:675\u201391.","journal-title":"Patient Prefer Adherence"},{"key":"2028_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.912785","volume":"9","author":"JL Katzmann","year":"2022","unstructured":"Katzmann\u00a0JL, et\u00a0al. Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021. Front Cardiovasc Med. 2022;9:912785.","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"2028_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100880","volume":"47","author":"S Talic","year":"2022","unstructured":"Talic\u00a0S, Marquina Hernandez\u00a0C, Ofori-Asenso\u00a0R, et\u00a0al. Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data. Current Problems in Cardiology. 2022;47(7)100880.","journal-title":"Current Problems in Cardiology"},{"issue":"6","key":"2028_CR25","first-page":"704","volume":"9","author":"E Aarnio","year":"2016","unstructured":"Aarnio\u00a0E, et al. Socioeconomic Inequalities in Statin Adherence Under Universal Coverage. Circulation: Cardiovascular Quality and Outcomes. 2016;9(6):704\u201313.","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"2028_CR26","unstructured":"Dutch 2019 Cardiovascular Risk Management guidelines (In Dutch: NHG standaard Cardiovasculair risicomanagement). Dutch 2019 Cardiovascular Risk Management guidelines (In Dutch: NHG standaard Cardiovasculair risicomanagement). 2019. https:\/\/richtlijnen.nhg.org\/standaarden\/cardiovasculair-risicomanagement."},{"key":"2028_CR27","unstructured":"Food and Drug Administration, Department of Health & Human Services. ANDA approval 079167. 2016."},{"key":"2028_CR28","unstructured":"Astra Zeneca. AstraZeneca settles litigation over CRESTOR patent - Press Release (updated 25 March 2013). 2013. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2013\/astrazeneca-crestor-patent-litigation-settled-25032013.html!."},{"issue":"2","key":"2028_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","volume":"92","author":"PH Jones","year":"2003","unstructured":"Jones\u00a0PH, Davidson\u00a0MH, Stein\u00a0EA, et\u00a0al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses . Am J Cardiol. 2003;92(2):152\u201360.","journal-title":"Am J Cardiol"},{"issue":"8","key":"2028_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005562","volume":"12","author":"MG Nanna","year":"2019","unstructured":"Nanna\u00a0MG, Wang\u00a0TY, Xiang\u00a0Q, et\u00a0al. Sex Differences in the Use of Statins in Community Practice. Circ Cardiovasc Qual Outcomes. 2019;12(8)e005562.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"2028_CR31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/gerona\/glx256","volume":"73","author":"R Ofori-Asenso","year":"2018","unstructured":"Ofori-Asenso\u00a0R, Jakhu\u00a0A, Curtis\u00a0AJ, et\u00a0al. A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged >65 Years. J\u00a0Gerontol A Biol Sci Med Sci. 2018;73(6):798\u2013805.","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-026-02028-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:02:06Z","timestamp":1774335726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-026-02028-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1007\/s12471-026-02028-8","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.\u00a0C.\u00a0Timmermans, M.\u00a0P.\u00a0Witvliet, J.A.\u00a0van Erkelens, J.\u00a0Reitsma, P.W.\u00a0Kamphuisen, C.\u00a0Camaro, P.W.\u00a0Danse and E.\u00a0K.\u00a0Arkenbout declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}